Vaccine may delay recurrence for advanced ovarian cancers
the ONA take:
According to preliminary findings presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer in Chicago, Illinois, researchers have found that a vaccine delayed cancer recurrence in women with stage III or IV ovarian cancers.
For the phase II study, researchers enrolled 31 women with stage III or IV ovarian cancer. Of those, 20 received the experimental immunotherapy and 11 did not. Results showed that those who did not receive the immunotherapy experienced a cancer recurrence in a median of 14.5 months, while those who did receive the vaccine have not yet reached the median time to recurrence. Thus far, the majority of the study population is beyond the 14.5 months.
"This was a preliminary study with promising results that may give women with advanced ovarian cancer an option for a maintenance regimen," said Jonathan Oh, MD, a gynecologic oncologist at Texas Oncology, P.A., in Dallas, Texas. "Additionally, the vaccine is very well tolerated."
The findings suggest that using a patient's own immune system to combat advanced ovarian cancer may be promising strategy to improve patient outcomes.
Researchers have found that a vaccine delayed cancer recurrence in women with stage III or IV ovarian cancers.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|